SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

May 05, 2016 16:01 ET

Atossa Genetics Announces First Quarter 2016 Financial Results and Provides Company Update

Conference Call to Be Held Today at 4:30 pm Eastern Time

SEATTLE, WA--(Marketwired - May 5, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced First Quarter ended March 31, 2016 financial results and provided an update on recent company developments.

Steve Quay, President and CEO, commented, "We were especially pleased to announce in early March, 2016 the opening for enrollment of our '007' trial, a Phase 2 clinical trial of intraductal fulvestrant administration in women with ductal carcinoma in situ (DCIS) or invasive breast cancer slated for mastectomy or lumpectomy. This study will assess the safety and tolerability of fulvestrant when delivered directly into breast milk ducts of these patients. We look forward to reviewing study data in the second half of the year and are optimistic about its outcomes. The primary endpoint of the clinical trial is to assess the safety and tolerability of intraductal administration of fulvestrant in women with DCIS or Stage 1 or 2 invasive ductal carcinoma prior to mastectomy or lumpectomy. The secondary objective of the study is to determine if there are changes in the expression of Ki67 as well as estrogen and progesterone receptors between a pre-fulvestrant biopsy and post-fulvestrant surgical specimen." Dr. Quay continued, "We are continuing in our strident efforts in identifying one or more additional drug candidates to enhance our business and drive shareholder value."

Recent Corporate Developments 

Atossa's important recent developments include the following:

  • In March 2016, Opened Phase 2 Clinical Trial of Intraductal Fulvestrant Administration in Women with DCIS or Breast Cancer in the United States, which is Called the '007 Trial

  • In December 2015, Completed Sale of Wholly-Owned Subsidiary, The National Reference Laboratory for Breast Health, Inc. (the "NRLBH")

  • Raised Approximately $2.2 Million in Working Capital through the Sale of Common Stock to Aspire Capital in the First Quarter of 2016

Q1 2016 Financial Results

As a result of the sale of the NRLBH in December 2015, we generated no revenue or cost of revenue for the three months ended March 2016. Revenue and cost of service from NRLBH activities are presented as discontinued operations for the three months ended 2015. The NLRBH had total net revenue of $1,871,137 and cost of revenue of $1,206,311, for the three months ended March 31, 2015, consisting of mainly pharmacogenomics testing.

Total operating expenses were $2,327,540 for the three months ended March 31, 2016, consisting of general and administrative (G&A) expenses of $2,177,569 and R&D expenses of $149,971. As a result of the sale of NRLBH, operating expenses related to the NRLBH are presented separately as discontinued operations for the three months ended March 31, 2015.

Operating expenses from continuing operations for three months ended March 31, 2016 decreased $945,132, or 29%, from $3,272,672 for the three months ended March 31, 2015, which consisted of G&A expenses of $2,361,026, R&D expenses of $565,801, and selling expenses of $345,845. The decrease in operating expenses is mainly attributed to the 2015 launch of new devices and services which are not being pursued in 2016 and investing more in new R&D programs in the first quarter of 2015 compared to 2016.

The Company recorded a net loss of $2,327,540, for the three months ended March 31, 2016. The loss from discontinued operations for the three months ended March 31, 2015 was $61,204.

Conference Call Information

Management will host a conference call today, May 5, 2016, at 4:30 pm Eastern Time to review the financial results and recent corporate developments. To listen to the call by phone, interested parties within the U.S. should call 1-866-652-5200 and International callers should call 1-412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at Details for the webcast may be found on the Company's IR events page at

A replay of the call will be available approximately one hour after the end of the call through June 5, 2016. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10085791.

About Atossa Genetics

Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

    March 31,     December 31,  
    2016     2015  
Current assets                
  Cash and cash equivalents   $ 2,882,657     $ 3,715,895  
  Restricted cash     275,000       275,000  
  Prepaid expense     227,936       193,293  
  Other current assets     -       110,663  
    Total current assets     3,385,593       4,294,851  
  Furniture and equipment, net     145,970       171,568  
  Intangible assets, net     1,492,121       1,700,565  
  Other assets     76,337       76,337  
    Total assets   $ 5,100,021     $ 6,243,321  
Liabilities and Stockholders' Equity                
Current liabilities                
  Accounts payable   $ 429,052     $ 814,448  
  Accrued expenses     169,001       463,676  
  Payroll liabilities     724,934       1,159,335  
  Other current liabilities     3,848       64,128  
    Total current liabilities     1,326,835       2,501,587  
Stockholders' equity                
  Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding     -       -  
  Common stock - $.001 par value; 75,000,000 shares authorized, 38,823,464 and 32,657,257 shares issued and outstanding     38,823       32,657  
  Additional paid-in capital     56,996,766       54,643,940  
  Accumulated deficit     (53,262,403 )     (50,934,863 )
    Total stockholders' equity     3,773,186       3,741,734  
  Total liabilities and stockholders' equity   $ 5,100,021     $ 6,243,321  
    For the Three Months Ended
March 31,
    2016     2015  
Net revenue     -       -  
Cost of revenue     -       -  
  Gross profit     -       -  
Selling expenses     -       345,845  
Research and development expenses     149,971       565,801  
General and administrative expenses     2,177,569       2,361,026  
  Total operating expenses     2,327,540       3,272,672  
Operating loss     (2,327,540 )     (3,272,672 )
Other expenses     -       (1,415 )
Loss before income taxes     (2,327,540 )     (3,274,087 )
Income taxes     -       -  
Loss from continuing operations   $ (2,327,540 )   $ (3,274,087 )
Loss from discontinued operations     -       (61,204 )
Net loss   $ (2,327,540 )   $ (3,335,291 )
Loss per common share from continuing operations - basic and diluted   $ (0.07 )   $ (0.13 )
Loss per common share from discontinued operations- basic and diluted     -       -  
Loss per common share - basic and diluted   $ (0.07 )   $ (0.13 )
Weighted average shares outstanding, basic and diluted     31,511,623       24,916,867  

Contact Information

  • Atossa Genetics Company Contact:

    Atossa Genetics Inc.
    Kyle Guse
    CFO and General Counsel
    (O) 800-351-3902

    Investor Relations Contact

    Scott Gordon
    CorProminence LLC
    377 Oak Street
    Concourse 2
    Garden City, NY 11530
    Office: 516.222.2560